Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.31). On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Trading Down 4.2%

ZURA stock traded down $0.23 during midday trading on Tuesday, hitting $5.10. The company’s stock had a trading volume of 348,700 shares, compared to its average volume of 649,721. The company has a market cap of $483.42 million, a PE ratio of -4.80 and a beta of 0.09. Zura Bio has a 12 month low of $0.98 and a 12 month high of $7.44. The firm’s 50-day moving average is $6.03 and its 200-day moving average is $5.13.

Insider Buying and Selling at Zura Bio

In other news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the stock in a transaction dated Thursday, February 26th. The shares were purchased at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the acquisition, the insider directly owned 6,552,725 shares of the company’s stock, valued at $40,954,531.25. This represents a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 14.23% of the stock is owned by insiders.

Hedge Funds Weigh In On Zura Bio

Several hedge funds and other institutional investors have recently modified their holdings of ZURA. Bank of America Corp DE lifted its holdings in shares of Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after buying an additional 9,966 shares during the period. AQR Capital Management LLC bought a new position in shares of Zura Bio during the 1st quarter valued at $72,000. JPMorgan Chase & Co. lifted its holdings in shares of Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares during the period. Jane Street Group LLC bought a new position in shares of Zura Bio during the 2nd quarter valued at $113,000. Finally, UBS Group AG lifted its holdings in shares of Zura Bio by 878.3% during the 3rd quarter. UBS Group AG now owns 305,329 shares of the company’s stock valued at $1,322,000 after buying an additional 274,118 shares during the period. 61.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on ZURA shares. Chardan Capital upped their price objective on Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Oppenheimer lowered their price objective on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. Finally, Wedbush started coverage on Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zura Bio presently has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.